- Home
- ATEX vs BIOA Comparison
ATEX vs BIOA Comparison
Compare ATEX & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATEX | BIOA |
|---|---|---|
| Founded | 1997 | 2015 |
| Country | United States | United States |
| Employees | N/A | 62 |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 732.6M | 681.9M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | ATEX | BIOA |
|---|---|---|
| Price | $63.14 | $16.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $50.00 | ★ $51.50 |
| AVG Volume (30 Days) | 306.7K | ★ 328.1K |
| Earning Date | 02-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.85 | N/A |
| Revenue | ★ $6,031,000.00 | N/A |
| Revenue This Year | $2.70 | $720.93 |
| Revenue Next Year | $10.04 | N/A |
| P/E Ratio | $16.51 | ★ N/A |
| Revenue Growth | ★ 43.90 | N/A |
| 52 Week Low | $17.58 | $3.79 |
| 52 Week High | $63.88 | $24.00 |
Technical Indicators
Market Signals| Indicator | ATEX | BIOA |
|---|---|---|
| Relative Strength Index (RSI) | 72.55 | 44.74 |
| Support Level | $20.36 | $15.74 |
| Resistance Level | N/A | $19.46 |
| Average True Range (ATR) | 3.50 | 1.34 |
| MACD | 0.48 | -0.12 |
| Stochastic Oscillator | 84.19 | 37.67 |
Price Performance
Historical ComparisonAbout ATEX Anterix Inc.
Anterix Inc is a United States-based company engaged in delivering broadband needed to modernize infrastructure for energy, transportation, logistics, and other industries. The company offers Private LTE for utilities which help to automate processes, monitor environmental conditions, enable artificial intelligence, and drive productivity.
About BIOA BioAge Labs Inc.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.